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Abstract: Despite its discovery a hundred years ago, vitamin D has emerged as one of the 
most controversial nutrients and prohormones of the 21st century. Its role in calcium 
metabolism and bone health is undisputed but its role in immune function and long-term 
health is debated. There are clear indicators from in vitro and animal in vivo studies that 
point to vitamin D’s indisputable role in both innate and adaptive immunity; however, the 
translation of these findings to clinical practice, including the care of the pregnant woman, 
has not occurred. Until recently, there has been a paucity of data from randomized 
controlled trials to establish clear cut beneficial effects of vitamin D supplementation 
during pregnancy. An overview of vitamin metabolism, states of deficiency, and the results 
of recent clinical trials conducted in the U.S. are presented with an emphasis on what is 
known and what questions remain to be answered.  
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1. Introduction 
In pregnancy, to understand the place and importance of micronutrients or any nutrient, we must go 
back to the beginning—at the time when the sperm fertilizes the egg and implantation 5–6 days later 
into the uterine wall. Seemingly on “autopilot”, the maternal milieu may affect the well-being of not 
only that developing embryo and later fetus, but generations of offspring to come. The circumstances 
of various famines, plights, and poverty during recent human existence show us this [1–3]. Yet, it 
requires painstaking and meticulous research to understand the role that maternal nutrition during 
conception and later pregnancy plays on fetal well-being.  
Much of what we know comes from observation and extrapolation from clinical patients with 
known nutrient imbalance or metabolic dyscrasias, from those afflicted with famine, and from animal 
studies. Yet, in those instances, we tend to focus on one nutrient and its effects if lacking or in excess. 
It is elementary, however, to think that one nutrient or micronutrient does not interact with other 
nutrients and chemicals within the body; instead of acting in isolation, there is a synergistic effect. 
Within the framework of the living being, there is a developmental and aging cascade that is not static, 
but which is in flux, such that findings on a given day may be valid for that day but become less 
applicable with additional growth or with the upregulation of involved enzymatic systems. While the 
complexity of what we are trying to predict and to understand may be evident with closer examination, 
we tend to generalize and to think that we know all we could about a given nutrient or micronutrient. 
Yet, decade after decade of scientific inquiry shows us not so much how right we are but how little we 
know in the grand scheme. It is with these cautions and confessions that we approach this review about 
vitamin D’s role during pregnancy. 
In the sections ahead, we will focus on one micronutrient—vitamin D—and will discuss what we 
know and what we surely do not know in the context of the pregnant woman and her developing fetus. 
During this foray into the world of vitamin D and the fetus, we must first define what vitamin D is, 
what it is not, and review the metabolic pathways linked with vitamin D. 
2. What Is Vitamin D? 
Vitamin D is a preprohormone that is made by most living plants and terrestrial animals. In the true 
sense of the word, vitamin D is not a “vitamin” because the main source of vitamin D is that which we 
synthesize ourselves—in our skin—with less than 10% coming from dietary sources. Vitamin D comes 
in two major forms—vitamin D2 or ergocalciferol and vitamin D3 or cholecalciferol. While certain 
plants are capable of making both forms of vitamin D, the major form made by plants is vitamin D2 
following ultraviolet B exposure of the provitamin D2 ergosterol [4,5]. In comparison, humans can 
metabolize both vitamin D2 and D3, but can only synthesize de novo vitamin D3. (For the purposes of 
this review, unless otherwise mentioned, when vitamin D and its metabolites are stated without a 
subscript, both families of vitamin D—cholecalciferols and ergocalciferols are described.) 
3. Sources of Vitamin D 
As shown in Figure 1, the de novo synthesis of vitamin D3 in humans and other animals begins in 
the skin with the parent compound 7-dehydrocholesterol or provitamin D3. Following exposure to Nutrients 2012, 4 
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ultraviolet B radiation in the range of 280–320 nm, 7-dehydrocholesterol becomes previtamin D3. 
Through a subsequent thermal reaction in the skin, previtamin D3 is isomerized into vitamin D3. It is 
important to note that unlike other steroid hormones in the body whose main substrate is cholesterol, 
vitamin D synthesis requires the 7-dehydrocholesterol precursor and sunlight at a specific wavelength 
and angle. Without this reaction, humans are dependent on dietary intake of vitamin D, which may be 
in the form of either vitamin D2 or D3. A western diet, however, provides less than 200 IU (5 μg) 
vitamin D/day, a point that was reestablished in our two recently completed vitamin D clinical trial 
during pregnancy [6].  
Figure 1. Human vitamin D synthesis pathways. Reproduced with permission from [7]. 
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4. General Vitamin D Metabolism 
In order to understand the differences between the nonpregnant and pregnant states and their effects 
on vitamin D metabolism, it is essential to understand the nonpregnant state first. Following its synthesis, 
vitamin D binds to vitamin D binding protein (VDBP) and finds its ways into the circulation. Dietary 
and endogenous vitamin D appear to act similarly with half-life between 12 and 24 h, the length of 
time depending on how quickly the liver converts vitamin D to 25-hydroxy-vitamin D (also known as 
calcidiol). Vitamin D is measured in international units (IU) or micrograms with a known conversion 
of 40 IU equal to 1 microgram.  
While there appears to be a differential conversion rate of the two forms of vitamin D to   
25(OH)D [8], the conversion of either form is dependent on a functional liver and the activity of  
25-hydroxylase. Thus, those with impaired liver function will have diminished conversion of vitamin D Nutrients 2012, 4 
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to 25(OH)D. Following its synthesis, 25(OH) then enters the circulation where it is tightly bound to 
VDBP. Only a small amount of 25(OH)D is unbound or “free”. The half-life of 25(OH)D is 2–3 weeks, 
making it a much better indicator of the body’s vitamin D status than vitamin D. Of note, 25(OH)D 
can be expressed as ng/mL or nmol/L. The conversion from ng/mL to nmol/L is 2.5; thus, a 25(OH)D 
concentration of 20 ng/mL equals 50 nmol/L. 
Once 25(OH)D is formed in the liver, it enters the circulation. Best known is the processing of 
25(OH)D by the kidney where 25(OH)D complexed with VDBP and megalin is taken up by   
the epithelial cells of the proximal tubules and converted to the active hormonal form of   
vitamin D—di-hydroxy-vitamin D (1,25(OH)2D or calcitriol)—by the action of the mitochondrial 
enzyme 1-α-hydroxylase.  
1,25(OH)2D’s endocrine effects include the following classic triad of action: (1) increase intestinal 
calcium (as Ca
2+ ions) absorption through the actions of calbindin; (2) increase urinary calcium 
reabsorption; and (3) regulation of parathyroid hormone in a negative feedback loop that allows 
calcium to be absorbed from the gastrointestinal tract, reabsorbed from urine, and metabolized from 
bone in order to maintain calcium homeostasis within the body. Because calcium is essential to all 
tissues and organs, particularly the heart, skeletal muscle and brain, the body will claim calcium if 
necessary from the skeleton. Adequate vitamin D must be on hand to provide enough substrate to form 
25(OH)D, which in turn, is converted to 1,25(OH)2D, whose half-life is 8 hours. In individuals with 
vitamin D deficiency, only trace amounts of vitamin D will be found in the body because whatever 
comes into the circulation is quickly converted to 25(OH)D and then to 1,25(OH)2D to maintain 
calcium homeostasis. 
5. Extrarenal Effects of Vitamin D: Modulating Immune Function 
For decades, it was thought that only the kidney has the capacity to metabolize 25(OH)D; however, 
extrarenal metabolism has been demonstrated in every organ system in the body [9–12]. During 
pregnancy, the placenta is probably the most prominent site for extra-renal activation of vitamin D [13]. 
It appears that the extrarenal function of vitamin D has more to do with immune function than with 
calcium metabolism and homeostasis. Support for this premise first came from the observations of 
Mellanby and others at the turn of the 20th century: during that time, Mellanby in his study of rachitic 
children and dogs noted an increased risk of respiratory infections in those afflicted [14,15]. Additional 
reports came from those working with tuberculosis patients and the beneficial effect of being in 
sunlight and outdoors in the treatment of the condition [16]. Weick [17] in 1967 and Rehman [18] in 
1994 independently observed that children with rickets appeared ill, with decreased energy and 
activity, and were more susceptible to respiratory illnesses. Despite these observations, it was 
concluded that the condition of vitamin D deficiency led to weakness and malnutrition and was not a 
direct effect of vitamin D on the immune system. The mechanism of action of these processes and 
health derangements would not be understood until the advent of molecular biology. 
Vitamin D appears to affect immune function in two ways: (1) upregulation of the innate immune 
system; and (2) downregulation of the adaptive immune system. Focusing on the innate immune 
system first, a major mechanism of action of vitamin D is via an endogenous antimicrobial peptide 
called cathelicidin (LL-37), which is generated in response to microbial invasion through activation of Nutrients 2012, 4 
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toll-2 receptors (TLR) on monocytes and macrophages [19–21]. Not surprisingly, the vitamin D 
receptor element (VDRE) is contained in the promoter region of the gene for LL-37. VDRE are found 
only in the LL-37 gene promoters of primates, suggesting that the ability of vitamin D to promote  
LL-37 antibacterial action is a relatively recent event in evolution. Both 1,25(OH)2D and 25(OH)D 
have the ability to induce the expression of cathelicidin in monocyte/macrophage and epidermal 
lineage in cells that simultaneously have the 25(OH)D hydroxylase [22].  
Significant support for the role of vitamin D in immune processes and function came in 2006 when 
Liu et al. published their landmark study in Science [19]. Serum samples taken from African American 
subjects with low 25(OH)D were inefficient in supporting cathelicidin mRNA induction; however, 
with the addition of 25(OH)D to those samples with low 25(OH)D levels this pattern was reversed. 
Thus, in this series of experiments, the addition of 25(OH)D3 restored the ability of sera from 
individuals with low 25(OH)D concentrations to support TLR2/1L-mediated induction of cathelicidin 
mRNA. A related study by Fabri et al. [23], showed that IFN-γ-mediated antimicrobial activity of 
human macrophages, especially important in HIV and tuberculosis patients, is dependent on vitamin D. 
Both study findings have implications for the pregnant woman and her developing fetus, but our 
understanding of such processes following maternal exposure to a pathogen or maternal infection 
remains scant. There is every reason to suggest that such processes are fully functional in the   
pregnant woman.  
Vitamin D’s role as a modulator of the immune system encompasses the adaptive immune system 
as well. 1,25(OH)2D not only has the ability to affect processes within macrophages and monocytes, 
but also in T and B lymphocytes as well. The vitamin D receptor (VDR) is found on activated (but not 
resting) human T- and B-lymphocytes. Whereas 1,25(OH)2D appears to activate the bacteriocidal 
process within macrophages and monocytes, it has different effects, that include suppression of T-cell 
proliferation and modulation of T-cell phenotype—with anti-inflammatory properties [24]. By binding 
to the VDR on T cells, 1,25(OH)2D acts to: (1) inhibit the proliferation of uncommitted TH (helper) 
cells and (2) promote the proliferation of immunosuppressive regulatory T cells, or TregS, with notable 
accumulation of these cells at sites of inflammation [22]. It appears that 1,25(OH)2D suppresses certain 
B cell functions such as proliferation and immunoglobulin production and retards the differentiation of 
B-lymphocyte precursors to mature plasma cells in vitro. These in vitro findings help to explain the 
significant association between vitamin D deficiency and autoimmune diseases, such as systemic lupus 
erythematosus [25], multiple sclerosis [26–35], rheumatoid arthritis [31,36,37], diabetes—both   
types 1 [31,38–42] and 2 [43–45], and certain cancers, such as colon [46–49], breast [50–55], and 
prostate [55–59]. Additionally, the role of vitamin D in immune function intensifies the need to 
establish vitamin D sufficiency during pregnancy.  
6. Role of Parathyroid Hormone During Pregnancy 
Throughout the lifecycle, parathyroid hormone or PTH’s main function is to maintain calcium 
homeostasis: PTH levels are inversely related to calcium concentrations in the blood, increasing when 
there is a decrease, and decreasing when there is an increase in calcium, acting through the parathyroid 
hormone 1 receptor (high levels in bone and kidney) and the parathyroid hormone 2 receptor (high 
levels in brain, placenta, and other endocrine tissues). In nonpregnant adolescents and adults, increased Nutrients 2012, 4 
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PTH is associated with lower circulating concentrations of ionized calcium, which is most often 
precipitated by vitamin D deficiency and decreased intestinal calcium absorption. Thus, PTH levels are 
related to vitamin D status as well: PTH upregulates 1-α-hydroxylase, the enzyme responsible for  
1-α-hydroxylation of 25(OH)D, converting 25(OH)D to 1,25(OH)2D. In individuals who have vitamin 
D deficiency, the body increases production of PTH to maintain 1,25(OH)2D and calcium homeostasis. 
If vitamin D deficiency is sustained, secondary hyperparathyroidism will result.  
It is interesting that during pregnancy alone and at no other time during the lifecycle there is an 
uncoupling of vitamin D metabolism from calcium such that by the end of the first trimester, 
1,25(OH)2D levels are more than double what they are during the nonpregnant state without concurrent 
changes in serum calcium concentrations [6]. It is not surprising, then that during pregnancy PTH as a 
marker of vitamin D status is a less reliable predictor than in nonpregnant adults [60–62]. Haddow et 
al, in their study of 430 African American and 586 Caucasian pregnant women living in Rhode Island 
at latitude 42° N, found a weak negative correlation between total circulating 25(OH)D and PTH  
(r = −0.074 and −0.137 for Caucasian and African American women, respectively), affected somewhat 
by seasonality.  
An earlier study by Okonofua et al. [63], in their study of healthy Asian and Caucasian pregnant 
women showed an inverse correlation between maternal serum 25(OH)D and PTH (r = −0.32,  
p < 0.002), a relationship that did not persist when the Asian and Caucasian women were considered 
separately. Not unexpectedly, there was an inverse relationship between calcium and PTH in the same 
women (r = −0.51, p < 0.0001); suggesting that serum calcium alone has a more profound effect on 
PTH during pregnancy. In contrast, Morley et al. [64] and Hamilton et al. [65] both reported slightly 
lower correlations between PTH and 25(OH)D (r = −0.18 (p < 0.001) and r = −0.24 (p < 0.001)), 
respectively, than did Okonofua et al. [63], but higher correlations than Haddow et al. [60]. While 
Okonofua, et al, suggest that normalization of maternal calcium and PTH would be useful endpoints in 
determining the success of vitamin D supplementation during pregnancy, more recent studies suggest 
that because PTH threshold estimates cannot be precisely defined, total circulating 25(OH)D alone is a 
better measure of maternal vitamin D status [60,64,65]. 
In our recently published National Institute of Child Health and Human Development   
(NICHD)-sponsored trial involving 350 women randomized to one of three treatment groups   
(400 (10 μg), 2000 (50 μg) or 4000 (100 μg) IU vitamin D3/day) who were followed from 12 weeks of 
gestation until delivery, there was a trend in all subjects of PTH being higher as the subjects 
progressed through pregnancy, but was not significantly different by treatment [6]. Decreases in 
circulating PTH were observed if the levels attained were analyzed by race only. The African 
American group clearly had decreased circulating PTH as circulating 25(OH)D levels increased.   
As with Haddow et al. [60], threshold estimates were not precisely defined for the three racial/ethnic 
groups or by treatment group.  
7. Vitamin D Deficiency 
Vitamin D deficiency is best understood in terms of bone disease: rickets during infancy and early 
childhood and osteopenia and osteoporosis in adulthood. With rickets, bone formation and 
development is seriously altered with severe vitamin D (i.e., substrate) deficiency. Beyond childhood, Nutrients 2012, 4 
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severe vitamin D deficiency can occur in young women, including those who are pregnant, with higher 
risk with advancing age in a woman’s lifecycle. While there can be some calcium loss during 
pregnancy through fetal demands and increased urinary calcium excretion which increases with 
advancing pregnancy, there is a rebound effect such that multiparous women are not at increased risk 
of osteopenia compared with nulliparous women. Throughout gestation, if a woman is vitamin D 
deficient, it appears to impact fetal bone health more than maternal [66–68]. In addition, based on 
rickets and osteoporosis data, it appears that bone health, which is linked with renal production of 
1,25(OH)2D and calcium metabolism is maintained at significantly lower levels of circulating vitamin D 
concentrations compared to other health factors such as immune function, which is dependent on 
delivery of 25(OH)D to cells of the target tissue. Thus, there are different deficiency set points: the risk 
of rickets increases significantly when total circulating 25(OH)D falls below 10 ng/mL (25 nmol/L) 
whereas cathelicidin mRNA expression as a marker of immune function continues to be suppressed 
until 25(OH)D circulating levels reach at least 20 ng/mL (50 nmol/L) [69]. 
What was striking in the previously mentioned independent studies by Haddow et al. [60], 
Hamilton et al. [65], and the NICHD vitamin D supplementation trial [70,71] was the high incidence 
of vitamin D deficiency during early pregnancy in women with darker pigmentation. Using the recently 
revised Institute of Medicine’s (IOM) 2010 criterion for vitamin D deficiency of total circulating 
25(OH)D < 20 ng/mL (50 nmol/L) [72], approximately 70% of the African American compared to 
35% of Caucasian women in the Rhode Island study had evidence of vitamin D deficiency during 
winter, with slight improvement during summer months compared to winter months in both groups. In 
the study by Hamilton et al. [65], 68% African American and 33% Hispanic women living at latitude 
32°N were deficient compared to 18% Caucasian women. Similarly, in the NICHD trial conducted in 
Charleston, SC, 75% African American, 30% Hispanic and 12% Caucasian women met the definition 
of vitamin D deficiency set forth by the IOM [70]. Yet, as mentioned earlier, based on the NICHD trial 
results, the optimization of 1,25(OH)2D production does not occur until total circulating 25(OH)D 
levels are at least 40 ng/mL (100nmol/L) [6]. Applying this new criterion to the data suggests that, with 
the present Western diet and lifestyle, without adequate supplementation, virtually all unsupplemented 
African American and many Hispanic women in the United States do not have optimal 1,25(OH)2D 
production. The significance of this is highlighted in the following sections of this review.  
8. A Global Perspective on Vitamin D Status of Women During Pregnancy 
With improved laboratory techniques for the measurement of vitamin D developed in the early 
1980’s [73], investigators began to measure the vitamin D status of pregnant women. It became 
evident that women of darker pigment, who had migrated from sunnier climates to the United 
Kingdom or France, for example, and who wore clothing that left little skin exposed were found to be 
the most deficient [74–79]. Yet, it was thought for the most part that vitamin D deficiency was rare and 
could be avoided through some sunlight exposure and a daily vitamin D intake of 200 IU (5 μg) [80]. 
Therefore, it came as quite a surprise when the first report of widespread vitamin D deficiency in U.S. 
women of childbearing age was reported by the Center for Disease Control (CDC) in 2002 [81].  
Using the Third National Health and Nutrition Examination Survey (NHANES III), 1988–94, it was 
found that 42% of African American women had serum 25(OH) concentrations below 15 ng/mL   Nutrients 2012, 4 
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(37.5 nmol/L) [81]. Applying the current IOM definition of deficiency—25(OH)D level <20 ng/mL  
(50 nmol/L)—to the dataset increases the prevalence to ~75% [72].  
Rates of deficiency reported during the past decade in the U.S. suggest that the degree of deficiency 
is greatest in those with darker pigmentation, i.e., African American women, but deficiency exists among 
Hispanic and Caucasian women who have limited access to sunlight, either through limited activity 
outdoors, type of clothing, cultural practices, or thorough use of sunscreen when outdoors [70,82].  
In two studies involving over 1000 pregnant woman in sunny South Carolina at 32°N, 75% African 
American, 33% Hispanic and 12% Caucasian women had frank deficiency [70,82], speaking to the 
extent and severity of this health problem.  
Another issue that plagues more industrialized nations is obesity. Women—including pregnant 
women, with a BMI greater than 30 are at increased risk of vitamin D deficiency [70]. The adipose 
tissue serves as a repository for vitamin D that does not get into the circulation. The problem may be 
further compounded by limited sunlight exposure and calorically rich but nutrient-poor diets such that 
multiple nutrients may be deficient, affecting both mother and her developing fetus. 
In other areas of the world, deficiency also is commonplace, again reflecting a woman’s lifestyle, 
degree of skin pigmentation, where she lives (i.e., the latitude and whether she is an urban dweller or 
lives in more rural areas), the time of year, and the most important factor—whether she has sunlight 
exposure [83]. Reports of profound deficiency among pregnant women, those with 25(OH)D 
concentrations <10 ng/mL (25 nmol/L) are common throughout the world: 18% of pregnant women 
studied in the UK [84], 25% in the UAE [85], 80% in Iran [86], 42% in northern India [87], 61% in 
New Zealand [88], 89.5% in Japan [89], and 60–84% of pregnant non-Western women in The Hague, 
Netherlands [90] had serum 25(OH)D concentrations <10 ng/mL (25 nmol/L). Interestingly, in a 
recent study involving 144 pregnant women in the greater Copenhagen area evaluated at 18, 32 and  
39 weeks of gestation, 1.4–4.3% had this degree of deficiency [91]; this lower rate may correlate with 
increased dietary intakes of fish. For those areas of the world with higher rates of deficiency, it appears 
that a long-standing unawareness of how vitamin D is made and of the short and long-term health 
consequences of vitamin D insufficiency has led to widespread insufficiencies in most populations.  
9. Vitamin D During Pregnancy—Why Is It Important? 
From the prior sections, it is clear that vitamin D deficiency during pregnancy is common 
throughout the world yet what effect does deficiency have on the mother and her developing fetus? 
There is a strong relationship between maternal and fetal (cord blood) circulating 25(OH)D   
levels [92–95] such that maternal vitamin D deficiency is mirrored by neonatal vitamin D deficiency. 
With severe maternal vitamin D deficiency, the fetus rarely may develop rickets in utero with 
manifestation at birth [96]. Such readily observable fetal and neonatal skeletal effects of profound 
vitamin D deficiency are easily understood in terms of cause and effect, but the more subtle effects of 
deficiency on the developing immune system, for example, and subsequent infection risk or immune 
dysfunction are more difficult to understand [19,84,97–99].  
Vitamin D status during pregnancy appears to play a role in fetal skeletal development, tooth 
enamel formation, and general fetal growth and development [76,77]. Mannion et al. [100], comparing 
growth parameters in newborn infants with the maternal intakes of milk and vitamin D during Nutrients 2012, 4 
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pregnancy, found an association between vitamin D intake during pregnancy and birth weight. They 
reported with every additional 40 IU (1 μg) of maternal vitamin D intake, there was an associated 11-g 
increase in birth weight. Pawley and Bishop [101] in their study of 108 pregnant women and their 
offspring found a significant association between umbilical cord 25(OH)D concentrations and head 
circumference at 3 and 6 months’ postnatal age that persisted after adjusting for confounding factors. 
Maghbooli et al. found significantly wider posterior fontanelle diameter in neonates of mothers with 
vitamin D deficiency (as defined by a 25(OH)D level <34.9 nmol/L or ~14 ng/mL) compared to 
neonates whose mothers were not deficient [102]. Beyond growth, recent reports of neonates followed 
prospectively for acute viral infections and bronchiolitis from respiratory syncytial virus (RSV) 
support the premise that these states of deficiency do impact on the health of the young infant and 
suggest a greater role of vitamin D beyond bone health [103–105]. 
McGrath and others continue to investigate whether there are lasting effects of fetal and early 
infancy vitamin D deficiency on later adult disease processes such as anatomical changes of the brain, 
schizophrenia, multiple sclerosis, certain cancers, cardiovascular disease, and various other autoimmune 
diseases such as diabetes and lupus [106–121]. Because vitamin D status has not been a consistent 
concern during pregnancy, long-term data are sparse. The few studies that have been conducted have 
focused more on discernible neonatal effects of vitamin D during pregnancy, rather than the long-latency 
and later health effects. Reports of neonatal seizures due to severe hypocalcemia or rickets in utero 
that is manifested at birth from severe maternal and thus fetal vitamin D deficiency are rare and do not 
further our understanding of potential epigenetic effects of vitamin D [122,123]. During pregnancy, 
supplementation with the current standard amount of vitamin D in prenatal vitamins—400 IU (10 μg) 
vitamin D/day—has minimal effect on circulating 25(OH)D concentrations in the mother and her 
infant at term [6,124]. It is also known that infants of women who were deficient throughout pregnancy 
will reach a state of deficiency more quickly and with greater severity than infants of women replete 
during pregnancy [96].  
While there are numerous epidemiological studies that bear evidence of the association between 
vitamin D deficiency and altered health, definitive proof in terms of randomized controlled trials is 
often lacking. For example, higher circulating 25(OH)D levels have been linked with improved 
glucose handling and beta-cell function [125], and a reduction in risk for a growing list of long   
latency diseases that include cardiovascular disease [57,126–130], multiple sclerosis [27,32,34],   
rheumatoid arthritis [36], systemic lupus erythematosus [25], type 1 and 2 diabetes [36], and various  
cancers [46,52,55,131–136], but critics counter that while such findings are intriguing, they do not 
provide definitive evidence of causality or a mechanism of action that come from randomized 
controlled trials, and may lead to what is referred to as “circular epidemiology” [137]. While we await 
the results of numerous clinical trials now underway to determine if there is a discernible effect of 
vitamin D in altering risk for various disease states to understand the role of vitamin D in health, it is 
important not to discount the mounting evidence from laboratory studies and prospective observation 
trials [103–105] that vitamin D—as a preprohormone—is essential in maintaining the immune system 
with profound implications [19,138–140].  
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10. Attaining Vitamin D Sufficiency: Sunlight and Dietary Supplementation 
A recent study by Luxwolda et al. gives invaluable insight into vitamin D status of darker 
pigmented individuals living in a sun-rich environment in eastern Africa [141]. The investigators 
measured total (25(OH)D) concentrations of thirty-five pastoral Maasai (age 34 ± 10 years, 43% male); 
and twenty-five Hadzabe hunter-gatherers (age 35 ± 12 years, 84% male) living in Tanzania. Those 
participating in the study had skin type VI (darkly pigmented), wore a moderate degree of clothing, 
spent the major part of the day outdoors, and avoided direct exposure to sunlight when possible. The 
mean serum 25(OH)D concentration of the Maasai was 47.6 ng/mL (range 23.2–66.8 ng/mL or   
119 nmo/L (range 58–167)). Similarly, the Hadzabe had a mean 25(OH)D concentration of   
43.6 ng/mL (range 28.4–68.4) or 109 nmol/L (range 71–171). These concentrations were not related to 
age, sex or BMI. The 25(OH)D concentrations of the Maasai and the Hadzabe are on average more 
than double the concentrations of Africans living in the United States and other industrial countries. 
With regard to safety, sunlight is superior to oral supplementation. One does not become vitamin D 
toxic from sunlight exposure; however, in comparison, people have become toxic from ingesting too 
much oral vitamin D. In an adult, it appears that the upper limit of tolerability of vitamin D is a daily 
consumption of thousands of international units of vitamin D—above 10,000 IU/day [142,143]. There 
is a safety mechanism in place with sunlight: sunlight-derived vitamin D triggers downregulation of 
certain enzyme systems and upregulation of others in the body to dispose of any vitamin D and its 
metabolites not needed by the body. Judicious sunlight exposure is not a clear cut entity; however, as 
too much sun exposure can lead to sunburn, photoaging, and skin cancer [144,145]. In addition, what 
amount of sunlight is sufficient to achieve optimal vitamin D status varies depending on a host of 
factors such as the time of day, the time of year, the latitude, degree of skin pigmentation, type and 
extend of clothing, body surface area exposed and one’s body mass index (BMI) [146]. Of note, in 
recent years, the health authorities in western countries have—to an increasing extent—warned against 
systematic sunlight exposure and solarium due to the well-documented side-effects and advocated 
regular use of sunscreen at sun exposure. A large proportion of the younger adult population may follow 
these guidelines, which may increase the risk of vitamin D deficiency. Since the modern diet supplies 
less than 10% of one’s total vitamin D requirements, if judicious sunlight exposure is not an option, 
then the only alternative for the pregnant woman is vitamin D supplementation. 
11. Effectiveness of Vitamin D Supplementation During Pregnancy 
There has been a paucity of studies evaluating the requirements and effects of vitamin D 
supplementation during pregnancy. The studies that were available in a Cochrane review more than a 
decade ago indicated that the Adequate Intake (AI) for vitamin D during pregnancy of 400 IU/day is 
grossly inadequate, especially with ethnic minorities [147]. As predicted by vitamin D pharmacokinetics, 
supplements of 1000 IU/day of vitamin D to pregnant women result in a 12.5 to 15.0 nmol/L increase 
in circulating 25(OH)D concentrations in both maternal and cord serum compared with 
nonsupplemented controls [75–77]. This premise is supported by our two randomized clinical trials 
involving vitamin D supplementation of pregnant women [6,148]. 
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Consistent with the NICHD trial results, another recently completed study funded by the Thrasher 
Research Fund where women were randomized to either 2000 (50 μg)- or 4000 IU (100 μg)  
vitamin D3/day showed that the while the mean change from maternal 25(OH)D baseline was   
12.2 ± 13.2 ng/mL in the 2000 IU group and 15.2 ± 12.9 ng/mL in the 4000 IU group (p = 0.16),  
the overall 25(OH)D rate of increase differed significantly between the two dose groups (p = 0.036) 
with a higher rate in the 4000 IU group. Mean infant 25(OH)D level (ng/mL) was 22.1 ± 10.3 in the 
2000 IU group and 27.0 ± 13.3 in the 4000 IU group (p = 0.024). Secondary analysis indicated that 
preterm birth and labor were inversely related to pre-delivery vitamin D status (preterm birth   
OR = 0.50 per 10 ng/mL, p = 0.002; preterm labor or birth OR = 0.72 per 10 ng/mL, p = 0.012), an 
effect that persisted even after controlling for race. There were no adverse events associated with 
vitamin D supplementation [148].  
Preliminary analysis of the two concurrent vitamin D pregnancy NICHD (n = 350) and Thrasher 
Research Fund (n = 157) trials was undertaken to assess the health characteristics and outcomes of this 
larger, combined group using a common data dictionary [150]. As noted above, in the NICHD trial, 
women were randomized to 400 IU (10 μg), 2000 IU (50 μg) or 4000 IU (100 μg)/day, stratified by 
race. In the Thrasher trial, participants were randomized to 2000 (50 μg) or 4000 IU (100 μg)/day, also 
stratified by race. All participants received study drugs from the same manufacturing lot. Studies 
administered identical questionnaires to produce comparable sociodemographic/clinical characteristics. 
Outcome measures included: (1) maternal baseline and delivery 25(OH)D; (2) neonatal 25(OH)D;  
(3) comorbidities of pregnancy: gestational diabetes, hypertensive disorders of pregnancy, infection—
any, bacterial vaginosis (BV), and preterm birth without preeclampsia. In the combined cohort, there 
were 110 in the control group, 197 in 2000 IU group, and 189 in the 4000 IU group. The treatment 
groups differed on the basis of parity (p = 0.022); insurance status (Medicaid status more common in 
the 2000 IU group p = 0.006); and education (higher education level in the 400 IU group, p = 0.012). 
No differences were noted between groups in baseline 25(OH)D (p = 0.24), but differences between 
groups were noted in vitamin D status within one month of delivery (p < 0.0001) and in cord blood  
(p = 0.0001), with improved status in the 4000-IU group overall. No differences were noted between 
groups in terms of independent or combined comorbidities of pregnancy. There was a trend where preterm 
birth without preeclampsia was lower with increasing 25(OH)D concentration (Odds Ratio (OR) 0.83 
(Confidence Interval (CI) 0.68–1.01); p = 0.057). The risk of combined comorbidities of pregnancy 
adjusted for race/ethnicity and study was significantly lower with increasing 25(OH)D concentration 
(Odds Ratio per 10 ng/mL increase in 25(OH)D: 0.84; 95% CI 0.74–0.96; p = 0.0095) [150]. 
The debate about what constitutes frank deficiency, insufficiency, and sufficiency continues [72,151]. 
The answer varies depending on the question—is the outcome bone integrity or immune function? 
There could be a different cut point for each category. Most would agree—including the Institute of 
Medicine in their most recent statement—that levels below 20 ng/mL (100 nmol/L) represent deficiency 
in the nonpregnant individual. There is less consensus with respect to pregnancy: based on our recent 
randomized controlled trial with pregnant women, it is clear that optimization of 1,25(OH)2D does not 
occur until total circulating 25(OH)D levels have reached 40 ng/mL (100 nmol/L) [6].  
The significance of these trials is that vitamin D status is improved with 4000 IU vitamin D3 taken 
daily to achieve: (1) optimization of 1,25(OH)2D production, and (2) improved cord blood 25(OH)D 
concentration. Having a higher 25(OH)D concentration was associated with improved health outcomes Nutrients 2012, 4 
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in both studies, but whether improved vitamin D status is a marker of some other parameter or a direct 
effect of vitamin D supplementation remains unclear at this time. Studies specifically designed and 
powered to answer the question of whether or not vitamin D supplementation leads to improved health 
outcomes—lower risk of preterm birth, preeclampsia, and infection remain to be done. We can 
conservatively say that while we do not understand completely the role of 1,25(OH)2D during 
pregnancy, achieving optimal production can be done safely with 4000 IU vitamin D3/day, which 
appears to be the amount of vitamin D that would be conservatively generated by the body with 
adequate sunlight exposure over the duration of gestation. 
13. Unanswered Questions and Direction of Future Research Endeavors 
There are many unanswered questions about vitamin D’s “true” role during pregnancy: At no other 
time during the lifecycle is 25(OH)D so closely linked with 1,25(OH)2D [6]. As mentioned earlier, 
during the pregnant state, 1,25(OH)2D reaches levels many-fold higher than during the nonpregnant 
state, levels that would be toxic due to hypercalcemia to the nonpregnant individual, but which are 
essential during pregnancy. Why is calcium metabolism uncoupled from 1,25(OH)2D during this time?  
A leading theory is that 1,25(OH)2D is important for maternal tolerance to the foreign antigens of 
the fetus whose DNA is only half that of the mother’s, and in certain cases such as conception 
involving a donor egg—completely foreign. It is interesting that epidemiological studies involving 
pregnant women with preeclampsia—a clinical picture of inflammation and vasculitis—vitamin D 
deficiency has been implicated [152–154]. More work is warranted in this area to understand the 
possible role of vitamin D deficiency in preeclampsia. 
The health effects data from vitamin D supplementation trials thus far, while tantalizing, are not 
conclusive in showing definitive “proof” for vitamin D as a potential candidate in the reduction of 
comorbidities of pregnancy, yet one cannot dismiss the strong correlation between reduced risk with 
increased serum 25(OH)D concentrations. Is vitamin D merely a marker of synergistic processes within 
the body? Is it a constellation of factors such as vitamin D acting in concert with vitamin A to create a 
healthful milieu? What about the interplay between genetics, epigenetics and daily fluxes in vitamin D 
status? Are those at greatest risk for vitamin D deficiency somehow protected by selective differences 
in vitamin D binding protein affinities and in the vitamin D receptor itself? If so, does substrate 
sufficiency—either through adequate sunlight exposure or vitamin D supplementation—saturate such 
effects, making them clinically irrelevant? What about vitamin D’s role in maintaining immune 
homeostasis during pregnancy? Looking carefully at the increasing number of epidemiological studies 
involving women with preeclampsia: is there a link with vitamin D deficiency where perhaps in certain 
women, there is loss of the vitamin D-mediated suppression of T cells that leads to a profound 
inflammatory reaction reminiscent of graft-vs.-host disease? In those women with a specific genetic 
repertoire—affinity for vitamin D and receptor processing—vitamin D deficiency may very well be 
the lost key to stopping the cascade of events. Only meticulous and well-designed clinical and 
translational science will lead to answers to these important questions.  
  Nutrients 2012, 4 
 
221
14. Conclusions 
The role of vitamin D during pregnancy and its effect on maternal and fetal health is just beginning 
to be understood. In the last five years, there has been an explosion of published data concerning the 
immune effects of vitamin D, yet little is known in this regard about the specific immune effects of 
vitamin D during pregnancy. What is clear, however, is that vitamin D deficiency during pregnancy is 
rampant throughout the world, including countries such as the United States and Great Britain. While 
there remains much to be discovered and learned about vitamin D’s effect on the mother and her 
developing fetus, there is enough evidence to support the premise that deficiency is not healthful for 
either the mother or fetus. In this regard, the Institute of Medicine raised the 25(OH)D concentration 
from 10 ng/mL (25 nmol/L) to 20 ng/mL (50 nmol/L). A recent randomized controlled trial with  
350 women of diverse racial and ethnic backgrounds showed that 4000 IU vitamin D/day is most 
effective in improving the vitamin D status of pregnant women, attaining circulating levels of at least 
40 ng/mL (100 nmol/L) for 25(OH)D, and was necessary to achieve optimal 1,25(OH)2D production. 
The average level of circulating 25(OH)D achieved in 4000 IU group in this RCT was 50 ng/mL, and 
thus corresponds to what an average circulating 25(OH)D level has been shown to be in tribal Africans 
living in their native environment [141]. The novel finding from this trial that 25(OH)D concentration 
drives 1,25(OH)2D production during pregnancy sets the stage for additional research endeavors to 
delineate this relationship only found during pregnancy and to undercover its mechanisms of action 
and its putative role in maternal immune tolerance to the fetus.  
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